Report License

$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off

Order Review

Lung Cancer Treatment Market - By Type (Carcinoid, Non-small & Small Cell), By Therapy [(Radiation, Immunotherapy (Durvalumab), Targeted (Bevacizumab), Chemotherapy], By End-user (Hospitals, Specialty Clinics, Homecare), Global Forecast, 2023–2032

Report ID: GMI5708
Selected License: $8,350
Discount: $2,505
Order Total: $5,845

Need assistance?

Call us or write to us:

What You Get?

Billing Information

Payment Method


creditCardImage
Top